four factor prothrombin complex concentrate
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Anticoagulation
Conditions
Anticoagulation, Anticoagulation Reversal
Trial Timeline
Mar 15, 2018 → Mar 31, 2022
NCT ID
NCT03473132About four factor prothrombin complex concentrate
four factor prothrombin complex concentrate is a approved stage product being developed by CSL for Anticoagulation. The current trial status is unknown. This product is registered under clinical trial identifier NCT03473132. Target conditions include Anticoagulation, Anticoagulation Reversal.
What happened to similar drugs?
1 of 3 similar drugs in Anticoagulation were approved
Approved (1) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03473132 | Approved | UNKNOWN |
Competing Products
7 competing products in Anticoagulation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Apixaban | Pfizer | Approved | 43 |
| VKA + Apixaban + dabigatran + rivaroxaban | Bristol Myers Squibb | Pre-clinical | 26 |
| Apixaban | Bristol Myers Squibb | Pre-clinical | 26 |
| Apixaban + Cofact (4-Factor PCC) + Beriplex P/N (4-Factor PCC) + Placebo (Saline solution) | Bristol Myers Squibb | Phase 1 | 29 |
| DOACs: Rivaroxaban, Dabigatran, Apixaban + Standard of care (Warfarin) | Bayer | Pre-clinical | 23 |
| Prismocitrate 18 | Baxter | Phase 3 | 44 |
| Prismocitrate 18 | Baxter | Phase 3 | 29 |